The QCMD (Quality Control for Molecular Diagnostic) is an external quality assurance programme that helps to monitor and improve quality within clinical laboratories. In response to the COVID-19 outbreak, a SARS-CoV-2 EQA programme has been launched to assess the sensitivity and specificity of assays which are routinely used for molecular detection of SARS-CoV-2 clinically.
In the latest SARS-CoV-2 EQA programme launched in 2021, laboratory using DiagCor’s GenoScreenTM SARS-CoV-2 qRT-PCR Assay (compatible with DiagCor's DiagPuroTM Nucleic Acid Extraction System and Genesis 96Q Real-time PCR System) has participated and attained fully proficient (100% Proficient; Highly satisfactory scores) status. SARS-CoV-2 variants (B.1.1298 & B.1.1.25) and samples with low copy number (2 dPCR Log10 copies/ml) were being successfully detected. DiagCor Life Science prioritizes high product quality and actively supports SARS-CoV-2 testing services in laboratories worldwide, thus contributing to fight against COVID-19.
Read more about GenoScreenTM SARS-CoV-2 qRT-PCR Assay here, and please get in touch to learn more.
Headquartered in Hong Kong with ISO 13485 accredited Quality Management System, DiagCor has been dedicated solely to molecular diagnostics (MDx) since 2006. The global leader in flow-through hybridization technology, the company offers a range of products, solutions and services related to RNA and DNA analysis. As well as providing MDx laboratory services to Asia Pacific practitioners, DiagCor develops and manufactures MDx products and solutions, and offers MDx medical translation services and MDx consulting.
DiagCor Life Science